Stockreport

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization [Yahoo! Finance]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65. The decision to discontinue this study i [Read more]